SR One

San Francisco, United States · VC · DeepTech Specialist

About

SR One SR One was founded in 1985 as GSK's corporate venture arm and spun out as an independent firm in 2020. Fund I raised $500M (2020), followed by Fund II at $600M (2023). The focus is early-stage biotech. translating groundbreaking science into next-generation medicines. The firm operates from San Francisco and London with a trans-Atlantic presence. Notable portfolio companies include CRISPR Therapeutics, Principia Biopharma, Turning Point Therapeutics, Nkarta, and Hotspot Therapeutics. The

Industries

Stage focus

Geography

Notable investments

CRISPR Therapeutics
Principia Biopharma
Turning Point Therapeutics
Nkarta

Request removal →

Raising from SR One?

I've worked with founders across the industrial stack. If SR One is on your list, I can help you map the introduction path, sharpen the narrative, and run a tight process.

Talk to Dan